✦ LIBER ✦

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

✍ Scribed by Mogens Bernsdorf; Christian Ingvar; Leif Jörgensen; Malgorzata K. Tuxen; Erik H. Jakobsen; Anna Saetersdal; Marie Louise Kimper-Karl; Niels Kroman; Eva Balslev; Bent Ejlertsen

Publisher: Springer US
Year: 2011
Tongue: English
Weight: 209 KB
Volume: 126
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-011-1352-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II neoadjuvant trial of anastroz

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

✍ Suleiman Massarweh; Yee L. Tham; Jian Huang; Krystal Sexton; Heidi Weiss; Anna T 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 361 KB

Phase 2 randomized trial of primary endo

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

✍ Vladimir F. Semiglazov; Vladislav V. Semiglazov; Garik A. Dashyan; Elena K. Zilt 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

## Abstract ## BACKGROUND. Few studies have compared primary neoadjuvant endocrine therapy with neoadjuvant chemotherapy in breast cancer patients. The need for preoperative chemotherapy with doxorubicin or taxanes may be reduced in postmenopausal patients with estrogen receptor (ER)‐positive and/